Loading
A phase 1/2 trial of AMXI-5001:Dose Escalation Phase I in ovarian cancer, prostate cancer and pancreatic ductal adenocarcinoma, run by AtlasMedx, Incorporated, now recruiting.
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies is a phase 1/2 interventional study registered as NCT04503265 by AtlasMedx, Incorporated, with 122 participants planned, started 2020-08-12 and due to reach its primary completion in 2026-08. Interventions recorded: AMXI-5001:Dose Escalation Phase I and AMXI-5001:Dose Expansion Phase II.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/